Not yet recruiting
Respiratory syncytial virus immunisation
Not yet recruitingSafety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease
Registered drug
Safety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease
Registered drug
- Disease:Respiratory syncytial virus immunisation
- Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
Countries:
Poland
Poland- Participants:0–17 years
- Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
- Sponsor:Pfizer Inc.
